ERBB2 and cancer: Eradication of CD20-, HER2-, or EGFR-positive cancer cells by therapeutic antibodies is driven by ADCC/CDC as well as ADCP.7 Immunomodulatory reagents can deplete specific immunosuppressive cells to enhance antitumor activities of the remaining T cells.